Real-world Effectiveness and Safety Study of T-Dxd in Chinese Metastatic Breast Cancer
- Sponsor
- Fudan University
- Study ID
- NCT05594082
- Status
- Unknown
Conditions
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Trastuzumab Deruxtecan — DRUGTrastuzumab Deruxtecan, 5.4 mg/kg ivgtt q3w
Study Details
The aim of this trial is to explore the real-world effectiveness and poteintial predictors in Chinese metastatic breast cancer patients.
Key Dates
- Start date
- Nov 1, 2021
- Status verified
- Mar 2023
- Primary completion
- Jul 1, 2024
- Completion
- Jul 1, 2024
Study Design
- Enrollment
- 150 participants (estimated)
Primary Outcome Measure
PFS [ Time Frame: 6 weeks ]
Related Studies
- Collection of Blood From Patients With CancerRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Harvesting Cells for Experimental Cancer TreatmentsEnrolling By Invitation · National Cancer Institute (NCI) · Bethesda, Maryland
- High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast CancerRecruiting · Carol Fabian, MD · Kansas City, Kansas
- Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer StudiesRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland